Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSP 301 (Olopatadine/Mometasone) in Seasonal Allergic Rhinitis
NCT03444506Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olopatadine + mometasone in seasonal allergic rhinitis (SAR) (5 arms), sponsored by Glenmark Pharmaceuticals. Primary endpoint: instantaneous Total Nasal Symptoms Score at 15 days. Started Jan 2014; status: completed.
02
Drugs
olopatadine + mometasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT03444506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444506.